None listed
Conditions
Interventions
Medical Device : 184 participants with indications of the 10 acupoints, would be randomly assigned to the BMA treatment group or treatment group in a 1:1 ratio. The assigned participants would be tre
Sponsors
Dongshin University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male or female patients aged 19-70 at the screening visit. 2) Patients diagnosed with atopic dermatitis by the Hanifin and Rajka crieria (more than 3 of 4 major symptoms and more than 3 of 23 minor symptoms). 3) Patients scored 10-40 in the Objective Scoring Atopic Dermatitis (SCORAD) index. 4) Patients who can read and write Korean and voluntarily submitted written consent with their signature.
Exclusion criteria
Exclusion criteria: 1) Patients with severe skin diseases other than atopic dermatitis or severe oozing and maceration of atopic lesions, who may affect the results of this study in the investigators’ opinion. 2) Patients with skin diseases due to other internal (e.g., liver diseases, renal failure, etc.), psychotic, or neurologic reasons who are expected to affect the results of this study. 3) Patients who have used systemic medications, including corticosteroids, antibiotics, immunosuppressants/immunomodulators (systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-?, etc.) within 1 month before the screening visit. Exceptionally, systemic antihistamines are allowed to administer during the trial within the dose on the randomization visit if they have been administered at a constant dose since 1 month before randomization. Reduction and discontinuation are permitted but increase is prohibited. 4) Other severe comorbidities (e.g., heart diseases, kidney diseases, liver diseases, respiratory diseases, malignancy, immunodeficiency, etc.) tdeemed inadequate by the principal investigator; the abnormality criteria for liver function is defined as aspartate transaminase (AST) or alanine transaminase (ALT) level 5 times higher than the upper limit of the analyzed institution, and those for renal function is defined as 3 times higher than the upper limit of the analyzed institution. 5) Severe or uncontrolled asthma (exacerbation of asthma requiring systemic corticosteroids for at least 3 days attacks more than 2 times per year) 6) Allergy to adhesives. 7) Pregnant, lactating women, or women planning pregnancy. 8) Others deemed inadequate by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective SCORAD index | — |
Secondary
| Measure | Time frame |
|---|---|
| Pruritus visual analogue scale (VAS);POEM(Patient-oriented Eczema Measure) | — |
Countries
Korea, Republic of
Contacts
Public ContactSoo-Yeon Park
Dongshin University
Outcome results
None listed